ReviewInsights into imaging2025
Risk factor analysis of iodinated contrast medium-related hypersensitivity reactions.
Review in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From knowing to acting: closing the emergency gap in contrast-induced anaphylaxis.European radiology · 2026Article
- Iodinated Contrast Media in Oncologic CT: A Narrative Review of Safety, Risk Stratification, and Practical Considerations.Diagnostics (Basel, Switzerland) · 2026Review
- Systematic evaluation and meta-analysis of the diagnostic accuracy of ultrasound contrast in predicting the efficacy of systemic therapy for advanced hepatocellular carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypersensitivity reactions caused by iodinated contrast media (ICM) are by definition type B adverse reactions and therefore, they are not predictable. To partially limit this uncertainty, since the 1980s, risk factors have been defined and published. Currently, there are so many risks that any patient undergoing a contrast-enhanced imaging examination would have at least one risk. This is not helpful and instead leads to uncertainty again. From both studies and clinical experience, we know that only a small percentage of patients develop hypersensitivity reactions after ICM administration. Therefore, we subjected the risks published to a critical analysis. Based on 126 publications, we identified 43 risks, which were divided into three categories (patient-related, contrast agent-related and management-related risks). We have also mentioned the appropriate management for each risk. After critical assessment, the risk status remains with a history of an ICM-hypersensitivity reaction, acute allergic symptoms, the culprit ICM and documentation errors (e.g., if an iodine allergy is mentioned, a latex allergy is incorrectly suspected as an ICM-allergy or the wrong trigger is documented). In addition, we found that several risks have been named differently, although they cover the same risk situation (e.g., chronic/severe disease and frequent ICM applications). Furthermore, for several of the published risks, no mitigation measures are available. Taken together, of the large number of published risks, only those with risk status should be used clinically in the future. Known risk factors do not influence the nature of type B reactions. Critical relevance statement For patient safety, it would be advisable in the future to consider the following three risks: a history of an ICM-hypersensitivity reaction, acute allergic symptoms and documentation errors (e.g., if an iodine allergy is mentioned, a latex allergy is incorrectly suspected as an ICM-allergy or the wrong trigger is documented). KEY POINTS: Risk factors are intended to limit the unpredictability of ICM hypersensitivity reactions. Currently, risks are nonspecific and ultimately apply to all patients. We found that identical factors are published under different names. Four risks are relevant: history of ICM-HSR, acute allergy, the culprit ICM and documentation/management errors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.